Lv6
1920 积分 2023-09-28 加入
Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
19天前
已完结
Understanding the therapeutic toolkit for inflammatory bowel disease
20天前
已完结
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
25天前
已完结
Biologics for the treatment of autoimmune renal diseases
2个月前
已完结
Pathogenic cellular and molecular mediators in lupus nephritis
2个月前
已完结
Siglecs as modulators of macrophage phenotype and function
3个月前
已完结
GenSci120, a humanized PD-1 agonistic monoclonal antibody, enhances the binding of both PD-L1 and PD-L2 to PD-1, and mitigates the symptoms of GVHD in a mouse model
3个月前
已完结
Systemic lupus erythematosus: latest insight into etiopathogenesis
4个月前
已完结
The role of stem cell factor and of alternative c-kit gene products in the establishment, maintenance and function of germ cells
4个月前
已关闭
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
5个月前
已完结
皖公网安备34019202002308
